PainReform (NASDAQ:PRFX) Stock Rating Reaffirmed by Maxim Group

PainReform (NASDAQ:PRFX)‘s stock had its “hold” rating reiterated by analysts at Maxim Group in a report issued on Thursday, Benzinga reports.

PainReform Stock Performance

Shares of PRFX stock opened at $0.64 on Thursday. The firm has a fifty day moving average of $0.59 and a 200-day moving average of $0.62. PainReform has a 52-week low of $0.53 and a 52-week high of $20.16. The stock has a market cap of $1.29 million, a price-to-earnings ratio of -0.02 and a beta of 0.54.

PainReform (NASDAQ:PRFX) last announced its quarterly earnings results on Thursday, August 15th. The company reported ($0.40) EPS for the quarter.

Institutional Trading of PainReform

A hedge fund recently raised its stake in PainReform stock. Armistice Capital LLC grew its position in PainReform Ltd. (NASDAQ:PRFX) by 76.9% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 276,000 shares of the company’s stock after purchasing an additional 120,000 shares during the period. Armistice Capital LLC owned about 13.60% of PainReform worth $132,000 as of its most recent filing with the SEC. Institutional investors own 37.28% of the company’s stock.

PainReform Company Profile

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations.